Shares of MedPlus Health Services witnessed a strong rally in intraday trading after the company reported robust financial results for the fourth quarter of FY26. Investor sentiment improved significantly following healthy growth in profit, revenue and operating margins.
The stock jumped more than 11% during the trading session and touched an intraday high of ₹1,020.35 on the BSE before giving up a small portion of gains later in the day. Despite the slight pullback, the stock continued to trade sharply higher while broader equity markets remained moderately positive.
MedPlus Reports Strong Q4 FY26 Financial Performance
MedPlus Health Services posted solid year-on-year growth across key financial metrics during the March quarter, supported by higher sales, operational efficiency improvements and continued expansion of its retail network.
Key Q4 FY26 Financial Highlights
- Net Profit stood at ₹63.97 crore, rising 24.6% compared to the same quarter last year
- Revenue from Operations increased to ₹1,864.39 crore, reflecting growth of 23.5% YoY
- EBITDA rose to ₹107.63 crore from ₹80.33 crore in the corresponding period last year
- EBITDA Margin improved to 5.8% compared to 5.3% a year earlier
The improvement in margins indicates better cost management and stronger operational performance as the company continues scaling its business across India.
Retail Expansion Continues to Support Growth
Founded in 2006 by Gangadi Madhukar Reddy, MedPlus has emerged as one of India’s largest pharmacy retail chains.
The company currently operates:
- More than 5,000 retail stores
- Across over 800 cities
- In 10 Indian states
MedPlus also employs more than 28,000 full-time employees across its operations.
Its extensive retail footprint has helped strengthen brand visibility and improve accessibility for customers across urban and semi-urban markets.
Diversified Healthcare and Retail Business Model
Apart from its core pharmacy retail business, MedPlus operates across multiple healthcare and pharmaceutical segments, helping diversify revenue streams.
Its business operations include:
- Wholesale pharmaceutical distribution
- Manufacturing and contract manufacturing
- Private label healthcare and wellness products
- Diagnostic and pathology centres
The company also follows an omni-channel retail strategy, allowing customers to purchase medicines and healthcare products through both offline stores and digital platforms.
Customers can place orders through:
- Mobile applications
- Website platforms
- WhatsApp-based ordering systems
- Physical retail stores
This integrated approach has supported customer convenience while strengthening recurring demand.
Investor Sentiment Improves After Earnings
The strong quarterly performance boosted investor confidence, especially amid improving profitability and stable revenue growth in the healthcare retail segment.
Market participants also reacted positively to the company’s improving EBITDA margins, which indicate better operational leverage as scale increases.
Healthcare retail businesses continue to remain in focus as organised pharmacy chains expand their market share through technology integration, supply-chain efficiencies and broader product offerings.
Conclusion
The sharp rise in MedPlus Health Services’ share price reflects positive market reaction to its strong Q4 FY26 financial performance. With double-digit growth in revenue, profit and operating margins, the company continues strengthening its position in India’s organised pharmacy retail sector through expansion, operational efficiency and its omni-channel healthcare platform.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.
